The U.S. Marijuana Index, which hit a trough at 72.93 on April 3, has since recovered, with the Canadian Senate's June 19 ratification of the bill to legalize recreational pot serving as a shot in the arm for all marijuana stocks.
Prime Minister Justin Trudeau announced Oct. 17 as the official date when recreational marijuana can be consumed without inviting legal penalties.
Recreational marijuana will fetch Canada $4.3 billion in sales in the first year following the legalization, according to CNN, which quoted research by Deloitte.
In the year-to-date period, the index has added a mere 0.8 percent compared to the 1.6-percent gain in the S&P 500 Index.
See Also: How To invest In Marijuana Stocks
The Index's Year-To-Date Performance
Source: Marijuana Index.com
Most U.S. states permit limited use of medical marijuana under certain circumstances, while nine states and the District of Columbia have legalized recreational marijuana.
When the regulatory environment eases, the U.S. represents vast potential for marijuana stakeholders. The U.S. legal cannabis market is expected to grow from $8.5 billion in 2017 to $11 billion in 2018, according to the latest estimates by Arcview Market Research and BDS Analytics.
By 2022, spending is expected to reach $23.4 billion, growing by a CAGR of 22 percent from 2018 to 2022.
Revisiting The Picks
At the start of the year, Benzinga alerted investors to five big opportunities in the marijuana space. This is how each of the stocks has performed through June 30:
- GW Pharmaceuticals PLC- ADR GWPH: up 5.7 percent.
- Canopy Growth Corp CGC: up 24 percent; uplisted to NYSE on May 23.
- Aphria Inc APHQF: down 39 percent, overvaluation concerns weighed on the stock.
- MedReleaf Corp MEDFF: up 22 percent.
- Scotts Miracle-Gro Co NYSE: SMG): down 21 percent.
5 Best Performers Year-To-Date
The five best performers with market caps over $200 million are:
- MARIMED Inc/SH SH MRMD: up 235 percent.
- iAnthus Capital Holdings Inc ITHUF: up 154 percent
- OrganiGram Holdings Inc OGRMF: up 25 percent.
- Canopy Growth: up 24 percent.
- MedReleaf: up 22 percent.
Cannabis investors can't afford to miss the Benzinga Cannabis Capital Conference, a premier gathering of investors and entrepreneurs painting an honest picture of the opportunities and challenges in cannabis investing. Space is limited—get your tickets before they sell out.
5 Pot Stocks That Could Take Off In The Second Half
As the market enters the second half of the year, here's a look at a few marijuana stocks that could make waves in the market. The picks were screened based on the following criteria and come in addition to the five stocks Benzinga highlighted at the start of the year:
- Market cap north of $200 million.
- Average volume over 15,000.
- Positive sales.
- Debt-to-capital ratio of less than 2 percent.
- The presence of upcoming catalysts.
Organigram Poised For Bumper Harvest
Organigram Holdings, which produces and sells medical marijuana in Canada, has its shares listed on the TSX Venture Exchange and the over-the-counter market in the U.S. It's one of the profitable marijuana growers.
In the recent second quarter, the company reported sales totaling the U.S. dollar equivalent of $2.4 million, up 123 percent year-over-year, and net income of $823,880. The volume of cannabis oil sold jumped about 300 percent.
Organigram expects production costs to fall further to a record low in Q3, thanks to record yields per plant and production efficiencies.
Organigram has struck partnerships that should help its expansion into Germany and Australia and signed supply agreements with the provinces of New Brunswick and Prince Edward Island for recreational marijuana.
Innovative Industrial: Financing The Pot Industry
Innovative Industrial Properties Inc IIPR is a REIT that operates in the medical cannabis industry.
Innovative Industrial reported Q1 total revenues of $2.764 million, more than double from a year ago, and adjusted funds from operations of 23 cents per share.
Cronos Fires On All Cylinders
Cronos Group Inc CRON has been expanding its production capacity higher from 6,650 kg annually. This would help the company take advantage of the emerging opportunity presented by the legalization of recreational marijuana.
Cronos shares may also benefit from institutional investments from Wall Street firms due its February uplisting to the Nasdaq.
The company has an ongoing relationship with Constellation Brands, Inc. STZ, with the latter picking up a 9.9-percent stake in the former.
Insys Adopts Cannabis Focus
Insys Therapeutics Inc INSY, a company engaged in the development of pharmaceutical cannabinoids and spray technology, recently announced a new R&D vision that shifts resources from opioids to cannabinoids. The company has three ongoing clinical trials: a late-stage study in infantile spasms, a mid-study in childhood absence epilepsy and another late-stage study in Prader-Willi syndrome.
Insys said it intends to collaborate on autism research with UC San Diego's Center for Medicinal Cannabis Research.
Kush Bottles: A Supplier Play
Kush Bottles Inc KSHB, a supplier of supplies and packaging mainly to marijuana growers and dispensaries, is another way play on the anticipated marijuana boom. The company has notched strong revenue growth in recent quarters.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.